FLT3 and acute myeloid leukemia: The following studies demonstrate synergistic effects between FLT3 inhibitors and ferroptosis inducers both in vitro and in vivo, suggesting a novel therapeutic strategy to enhance sensitivity or overcome resistance to gilteritinib in FLT3-mutant AML [109].